GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (FRA:AN6) » Definitions » Stock Based Compensation

AnaptysBio (FRA:AN6) Stock Based Compensation : €30.81 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Stock Based Compensation?

AnaptysBio's Stock Based Compensation for the three months ended in Dec. 2023 was €7.44 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was €30.81 Mil.


AnaptysBio Stock Based Compensation Historical Data

The historical data trend for AnaptysBio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Stock Based Compensation Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.17 9.45 13.59 25.83 30.45

AnaptysBio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.32 8.28 7.78 7.32 7.44

AnaptysBio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €30.81 Mil.


AnaptysBio Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (FRA:AN6) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.

AnaptysBio (FRA:AN6) Headlines

No Headlines